In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

Author： Kaplan Nachum  

Publisher： Maney Publishing

ISSN： 1973-9478

Source： Journal of Chemotherapy, Vol.25, Iss.1, 2013-02, pp. : 18-25

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics

By Tsuji Brian T  

Journal of Chemotherapy, Vol. 25, Iss. 1, 2013-02 ,pp. : 32-35

Maney Publishing

Access to resources Recommend Favorite

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

By Banevicius Mary A  

Journal of Chemotherapy, Vol. 25, Iss. 1, 2013-02 ,pp. : 26-31

Maney Publishing

Access to resources Recommend Favorite

Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs

By Fiegl Michael  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 2, 2008-07 ,pp. : 321-329

Springer Publishing Company

Access to resources Recommend Favorite

Enhanced antitumor activity by the combination of dasatinib and combretastatin A-4 in vitro and in vivo

By                    

Oncology Reports, Vol. 29, Iss. 6, 2013-01 ,pp. : 2275-2282

Spandidos Publications

Access to resources Recommend Favorite

Maspin-A Novel Protease Inhibitor with Tumor-suppressing Activity in Breast Cancer

By Maass Nicolai   Hojo Takashi   Zhang Ming   Sager Ruth   Jonat Walter   Nagasaki Koichi  

Acta Oncologica, Vol. 39, Iss. 8, 2000-11 ,pp. : 931-934

Informa Healthcare

Access to resources Recommend Favorite